Infiuss Health GTM brain

category

market profile

• text: Trial teams must choose protocols and sample sizes before seeing actual patient outcomes; Infiuss now positions itself around rehearsal before enrollment.
• text: Earlier offerings focused on remote recruitment and diverse clinical research populations in Africa, so historical descriptions may not reflect the current homepage positioning.

personas

• title: Clinical development leader at a biotech sponsor
  pains:

  • Protocol assumptions can drive expensive late failures
  • Enrollment delays consume development time and cash
• title: Biostatistics and trial design lead
  pains:

  • Must justify sample size and power assumptions
  • Needs to compare endpoints, cohorts and trial arms before protocol lock
• title: CRO clinical operations director
  pains:

  • Sponsors need defensible feasibility decisions sooner
  • Recruiting excess participants increases trial complexity

icp

• text: Biotech and pharmaceutical sponsors and CROs designing interventional clinical studies.
• text: Trial design teams with access to historical trial data, registries or real-world clinical data and an upcoming protocol decision.

message pillars

• text: Rehearse a protocol before enrolling patients.
• text: Validate models against real-world outcomes.
• text: Make design assumptions reviewable by statisticians and regulators.

objections

• objection: Can simulated patients be trusted for trial design?
  response: Request held-out validation and review the data, assumptions and power calculations with your biostatistics team.
• objection: Does simulation replace evidence from real patients?
  response: Position rehearsal as an input to protocol design and planning alongside real clinical research.

competitors

• name: Unlearn
  why: Patient digital twins and clinical trial design are adjacent alternatives.
• name: TrialWire
  why: Patient recruitment alternative for trial teams focused on enrollment rather than simulated protocol design.

influencers

• name: Melissa Bime
  url: https://www.wearetech.africa/en/fils-uk/tech-stars/melissa-bime-finds-the-right-participants-for-clinical-trials-in-africa
  why: Founder with public commentary on clinical trial access in Africa.

keywords

• clinical trial digital twins
• clinical trial simulation
• protocol optimization
• synthetic control arms
• clinical trial sample size
• patient recruitment feasibility

voice

• Evidence-led
• Direct and outcome-focused
• Clinically technical

signals

• text: A sponsor is preparing a protocol and evaluating eligibility, endpoints or sample size.
• text: A trial team reports recruitment delays or is testing adaptive trial design options.

pricing

motion

channels

• website
• clinical research content

confidence

Founders

• name: Melissa Bime
  title: Founder
  role: Founder
  bio: Melissa Bime is the co-founder of Infiuss Health. She is a RN, and has got to experience first hand the challenges patients faced across diverse health care settings in Africa. After completing Nursing school, Melissa started INFIUSS, a startup that connects life science companies to patients for clinical research and clinical trials in Africa to help ensure that Africa’s Diverse population is included in global research studies and clinical trials.